[INFO] Stripe initialized successfully
[INFO] ***Starting server initialization...


[INFO] Registering routes...
[INFO] Setting up Vite for development...
[INFO] Stripe initialized successfully
[INFO] ***Starting server initialization...


[INFO] Registering routes...
[INFO] Setting up Vite for development...
[INFO] Server started successfully on port 4000
[INFO] Webhook endpoint available at: https://PodCasterella.VivekGopal1.repl.co/api/webhooks/stripe
[INFO] GET / 200 in 35ms
[INFO] GET /@vite/client 304 in 17ms
[INFO] GET /src/main.tsx 304 in 37ms
[INFO] GET /@react-refresh 304 in 1ms
[INFO] GET /src/index.css 304 in 641ms
[INFO] GET /@vite-plugin-checker-runtime 304 in 1565ms
[INFO] GET /src/lib/queryClient.ts 304 in 1ms
[INFO] GET /src/components/ui/toaster.tsx 304 in 1ms
[INFO] GET /src/pages/AuthPage.tsx 304 in 1ms
[INFO] GET /src/pages/HomePage.tsx 304 in 1ms
[INFO] GET /src/pages/PricingPage.tsx 304 in 1ms
[INFO] GET /src/pages/LibraryPage.tsx 304 in 1ms
[INFO] GET /src/pages/AdminPage.tsx 304 in 0ms
[INFO] GET /src/pages/ProfilePage.tsx 304 in 0ms
[INFO] GET /src/pages/BillingPage.tsx 304 in 1ms
[INFO] GET /src/pages/FeedbackPage.tsx 304 in 0ms
[INFO] GET /src/components/Sidebar.tsx 304 in 1ms
[INFO] GET /src/components/ui/button.tsx 304 in 1ms
[INFO] GET /@fs/home/runner/PodCasterella/node_modules/vite/dist/client/env.mjs 304 in 0ms
[INFO] GET /src/hooks/use-user.ts 304 in 1ms
[INFO] GET /src/pages/ForgotPasswordPage.tsx 304 in 0ms
[INFO] GET /src/hooks/use-tts.ts 304 in 0ms
[INFO] GET /src/components/ui/toast.tsx 304 in 0ms
[INFO] GET /src/hooks/use-toast.ts 304 in 0ms
[INFO] GET /@fs/home/runner/PodCasterella/db/schema.ts 304 in 1ms
[INFO] GET /src/components/ui/input.tsx 304 in 0ms
[INFO] GET /src/components/Logo.tsx 304 in 1ms
[INFO] GET /src/components/ui/form.tsx 304 in 0ms
[INFO] GET /src/components/UsageProgress.tsx 304 in 0ms
[INFO] GET /src/components/ui/collapsible.tsx 304 in 1ms
[INFO] GET /src/components/ui/alert-dialog.tsx 304 in 1ms
[INFO] GET /src/lib/utils.ts 304 in 1ms
[INFO] GET /src/components/AudioPlayer.tsx 304 in 1ms
[INFO] GET /src/hooks/use-audio.ts 304 in 0ms
[INFO] GET /src/components/ui/card.tsx 304 in 0ms
[INFO] GET /src/components/ui/tabs.tsx 304 in 1ms
[INFO] GET /src/components/ui/avatar.tsx 304 in 1ms
[INFO] GET /src/components/ui/separator.tsx 304 in 1ms
[INFO] GET /src/components/PaymentModal.tsx 304 in 0ms
[INFO] GET /src/components/LoadingScreen.tsx 304 in 1ms
[INFO] GET /src/components/ui/textarea.tsx 304 in 0ms
[INFO] GET /src/components/ui/scroll-area.tsx 304 in 1ms
[INFO] GET /src/components/ui/label.tsx 304 in 1ms
[INFO] GET /src/components/ui/select.tsx 304 in 1ms
[INFO] GET /src/components/ui/progress.tsx 304 in 1ms
[INFO] GET /src/components/ui/slider.tsx 304 in 0ms
[INFO] GET /src/components/ui/popover.tsx 304 in 0ms
[INFO] GET /src/components/ui/dialog.tsx 304 in 1ms
[INFO] GET /api/user 401 in 3ms
[INFO] GET / 200 in 6ms
[INFO] GET /src/main.tsx 304 in 1ms
[INFO] GET /@vite/client 304 in 1ms
[INFO] GET /@react-refresh 304 in 0ms
[INFO] GET /@vite-plugin-checker-runtime 304 in 0ms
[INFO] GET /src/index.css 304 in 1ms
[INFO] GET /src/components/ui/toaster.tsx 304 in 0ms
[INFO] GET /src/pages/AuthPage.tsx 304 in 0ms
[INFO] GET /src/pages/HomePage.tsx 304 in 0ms
[INFO] GET /src/lib/queryClient.ts 304 in 1ms
[INFO] GET /src/pages/PricingPage.tsx 304 in 0ms
[INFO] GET /src/pages/LibraryPage.tsx 304 in 0ms
[INFO] GET /src/pages/ProfilePage.tsx 304 in 1ms
[INFO] GET /src/pages/AdminPage.tsx 304 in 1ms
[INFO] GET /src/pages/BillingPage.tsx 304 in 1ms
[INFO] GET /src/hooks/use-user.ts 304 in 1ms
[INFO] GET /src/pages/FeedbackPage.tsx 304 in 1ms
[INFO] GET /src/components/Sidebar.tsx 304 in 0ms
[INFO] GET /src/components/ui/button.tsx 304 in 1ms
[INFO] GET /src/pages/ForgotPasswordPage.tsx 304 in 1ms
[INFO] GET /src/components/ui/toast.tsx 304 in 0ms
[INFO] GET /src/hooks/use-toast.ts 304 in 1ms
[INFO] GET /src/hooks/use-tts.ts 304 in 0ms
[INFO] GET /src/components/ui/input.tsx 304 in 1ms
[INFO] GET /src/components/Logo.tsx 304 in 1ms
[INFO] GET /@fs/home/runner/PodCasterella/node_modules/vite/dist/client/env.mjs 304 in 0ms
[INFO] GET /src/components/ui/collapsible.tsx 304 in 1ms
[INFO] GET /@fs/home/runner/PodCasterella/db/schema.ts 304 in 1ms
[INFO] GET /src/components/ui/alert-dialog.tsx 304 in 1ms
[INFO] GET /src/components/ui/form.tsx 304 in 1ms
[INFO] GET /src/components/UsageProgress.tsx 304 in 1ms
[INFO] GET /src/hooks/use-audio.ts 304 in 1ms
[INFO] GET /src/components/AudioPlayer.tsx 304 in 2ms
[INFO] GET /src/components/PaymentModal.tsx 304 in 0ms
[INFO] GET /src/components/ui/avatar.tsx 304 in 1ms
[INFO] GET /src/components/ui/card.tsx 304 in 1ms
[INFO] GET /src/components/ui/separator.tsx 304 in 0ms
[INFO] GET /src/lib/utils.ts 304 in 2ms
[INFO] GET /src/components/ui/tabs.tsx 304 in 0ms
[INFO] GET /src/components/LoadingScreen.tsx 304 in 0ms
[INFO] GET /src/components/ui/textarea.tsx 304 in 0ms
[INFO] GET /src/components/ui/scroll-area.tsx 304 in 3ms
[INFO] GET /src/components/ui/label.tsx 304 in 0ms
[INFO] GET /src/components/ui/progress.tsx 304 in 1ms
[INFO] GET /src/components/ui/popover.tsx 304 in 18ms
[INFO] GET /src/components/ui/slider.tsx 304 in 1ms
[INFO] GET /src/components/ui/select.tsx 304 in 3ms
[INFO] GET /src/components/ui/dialog.tsx 304 in 1ms
[INFO] GET /api/user 401 in 1ms
[INFO] GET / 200 in 10ms
[INFO] POST /api/login 200 in 359ms
[INFO] GET /api/user 304 in 60ms
[INFO] GET / 200 in 59ms
[INFO] 
========Streaming audio file: 1735923996260-article.mp3
[ERROR] File not found in Object Storage: 1735923996260-article.mp3
[INFO] GET /api/audio/stream/1735923996260-article.mp3 404 in 212ms
[INFO] GET /api/podcasts 304 in 348ms
[INFO] GET /api/playlists 304 in 369ms
[INFO] 
========Streaming audio file: 1735923996260-article.mp3
[ERROR] File not found in Object Storage: 1735923996260-article.mp3
[INFO] GET /api/audio/stream/1735923996260-article.mp3 404 in 148ms
[INFO] GET / 200 in 59ms
[INFO] GET /@vite/client 304 in 56ms
[INFO] GET /@vite-plugin-checker-runtime 304 in 101ms
[INFO] GET /@react-refresh 304 in 157ms
[INFO] GET /src/main.tsx 304 in 212ms
[INFO] GET /@fs/home/runner/PodCasterella/node_modules/vite/dist/client/env.mjs 304 in 144ms
[INFO] GET /src/pages/AuthPage.tsx 304 in 67ms
[INFO] GET /src/pages/HomePage.tsx 304 in 121ms
[INFO] GET /src/index.css 304 in 175ms
[INFO] GET /src/pages/LibraryPage.tsx 304 in 220ms
[INFO] GET /src/lib/queryClient.ts 304 in 235ms
[INFO] GET /src/pages/PricingPage.tsx 304 in 216ms
[INFO] GET /src/components/ui/toaster.tsx 304 in 234ms
[INFO] GET /src/pages/AdminPage.tsx 304 in 277ms
[INFO] GET /src/pages/ProfilePage.tsx 304 in 289ms
[INFO] GET /src/pages/BillingPage.tsx 304 in 288ms
[INFO] GET /src/pages/FeedbackPage.tsx 304 in 291ms
[INFO] GET /src/hooks/use-user.ts 304 in 287ms
[INFO] GET /src/components/Sidebar.tsx 304 in 289ms
[INFO] GET /src/pages/ForgotPasswordPage.tsx 304 in 288ms
[INFO] GET /src/components/ui/button.tsx 304 in 287ms
[INFO] GET /@fs/home/runner/PodCasterella/db/schema.ts 304 in 287ms
[INFO] GET /src/components/ui/input.tsx 304 in 292ms
[INFO] GET /src/components/ui/form.tsx 304 in 292ms
[INFO] GET /src/hooks/use-toast.ts 304 in 290ms
[INFO] GET /src/hooks/use-tts.ts 304 in 294ms
[INFO] GET /src/components/Logo.tsx 304 in 287ms
[INFO] GET /src/components/UsageProgress.tsx 304 in 293ms
[INFO] GET /src/components/ui/collapsible.tsx 304 in 289ms
[INFO] GET /src/components/ui/alert-dialog.tsx 304 in 295ms
[INFO] GET /src/hooks/use-audio.ts 304 in 293ms
[INFO] GET /src/components/AudioPlayer.tsx 304 in 248ms
[INFO] GET /src/lib/utils.ts 304 in 292ms
[INFO] GET /src/components/ui/toast.tsx 304 in 291ms
[INFO] GET /src/components/ui/card.tsx 304 in 290ms
[INFO] GET /src/components/ui/tabs.tsx 304 in 291ms
[ERROR] Webhook signature verification failed: No signatures found matching the expected signature for payload. Are you passing the raw request body you received from Stripe? 
 If a webhook request is being forwarded by a third-party tool, ensure that the exact request body, including JSON formatting and new line style, is preserved.

Learn more about webhook signing and explore webhook integration examples for various frameworks at https://docs.stripe.com/webhooks/signature

[INFO] POST /api/webhooks/stripe 400 in 2ms
[INFO] GET /src/components/ui/avatar.tsx 304 in 289ms
[INFO] GET /src/components/PaymentModal.tsx 304 in 289ms
[INFO] GET /src/components/LoadingScreen.tsx 304 in 288ms
[INFO] GET /src/components/ui/separator.tsx 304 in 291ms
[INFO] GET /src/components/ui/textarea.tsx 304 in 293ms
[INFO] GET /src/components/ui/scroll-area.tsx 304 in 291ms
[INFO] GET /src/components/ui/label.tsx 304 in 291ms
[INFO] GET /src/components/ui/progress.tsx 304 in 291ms
[INFO] GET /src/components/ui/slider.tsx 304 in 290ms
[INFO] GET /src/components/ui/select.tsx 304 in 291ms
[INFO] GET /src/components/ui/popover.tsx 304 in 291ms
[INFO] GET /src/components/ui/dialog.tsx 304 in 291ms
[INFO] GET /api/user 304 in 57ms
[INFO] GET / 200 in 103ms
[INFO] GET / 200 in 58ms
[INFO] 
========Streaming audio file: 1735923996260-article.mp3
[ERROR] File not found in Object Storage: 1735923996260-article.mp3
[INFO] GET /api/audio/stream/1735923996260-article.mp3 404 in 81ms
[INFO] 
========Streaming audio file: 1735923996260-article.mp3
[ERROR] File not found in Object Storage: 1735923996260-article.mp3
[INFO] GET /api/audio/stream/1735923996260-article.mp3 404 in 123ms
[INFO] GET /api/podcasts 304 in 284ms
[INFO] GET /api/playlists 304 in 339ms
[INFO] GET / 200 in 62ms
[INFO] Usage check for user: inactive
[INFO] GET /api/user/usage/check 304 in 166ms
[INFO] 

 PDF has 3 pages
[INFO] Calculating estimated pricing and checking usage limits
[INFO] 
======= Starting Pricing Calculation ======
 -Input text length: 16704
 -Number of Vertex AI responses: 0

[INFO] 
        Input text length: 16704
        Input token count: 3419
        System prompt length: 2718
        System token count: 525
        Total input tokens: 3944
      
[INFO] 
---***** Estimated Calculation Summary **** ---
Total Input Tokens: 3944
Total Output Tokens: 5916
Total Tokens: 9860
Total TTS Characters: 23664
Vertex AI Input Cost: $0.000002
Vertex AI Output Cost: $0.000003
TTS Cost: $0.378624
Total Cost: $0.378629
[INFO] Estimated Podify Tokens: 190 

Usage limits check for user 26:
 Current articles: 1/3
 Current Podify tokens: 34/10000
 Would exceed article limit: false
 Would exceed token limit: false
[INFO] Starting audio generation process
[INFO] 
--- Starting Conversation Generation ---

[INFO] Processing 13 lines of text
[INFO] Added conversation part: Joe with Welcome to Science Odyssey, the podcast where we j...
[INFO] Added conversation part: Sarah with Oh, I've heard whispers of this.  It sounds… messy...
[INFO] Added conversation part: Joe with Exactly.  They're crucial.  Think about it – scien...
[INFO] Added conversation part: Sarah with So, false positives, essentially?  Or even worse, ...
[INFO] Added conversation part: Joe with It's incredibly widespread.  There was this study,...
[INFO] Added conversation part: Sarah with Whoa. Three thousand citations based on faulty dat...
[INFO] Added conversation part: Joe with It's not that simple.  It's a combination of facto...
[INFO] Added conversation part: Sarah with So, what's being done to fix this?  Is it just a m...
[INFO] Added conversation part: Joe with It's more than that.  There are several initiative...
[INFO] Added conversation part: Sarah with That sounds promising.  It's a huge undertaking, t...
[INFO] Added conversation part: Joe with Oh yeah, it's a massive project.  But, um, it's cr...
[INFO] Added conversation part: Sarah with It's a great example of how seemingly small, techn...
[INFO] Added conversation part: Joe with My pleasure, Sarah. It's a vital issue for the sci...
[INFO] Successfully extracted 13 conversation parts
[INFO] Cleaned Text (Chunk 1): [
  {
    "speaker": "Joe",
    "text": "Welcome to Science Odyssey, the podcast where we journey through groundbreaking scientific studies, unraveling the mysteries behind the research that shapes our world. Thanks for tuning in!  So, Sarah, today we're diving into a fascinating—and frankly, a bit frustrating—problem in biomedical research: unreliable antibodies."
  },
  {
    "speaker": "Sarah",
    "text": "Oh, I've heard whispers of this.  It sounds… messy.  I mean, antibodies are fundamental to so much biological research, right?  What's the core issue?"
  },
  {
    "speaker": "Joe",
    "text": "Exactly.  They're crucial.  Think about it – scientists use antibodies to, um, identify and quantify specific proteins within cells.  But the problem is, many commercially available antibodies, you know, the ones researchers buy, simply don't work as advertised.  They might not bind to the *right* protein, or they might bind to multiple proteins, giving you completely misleading results."
  },
  {
    "speaker": "Sarah",
    "text": "So, false positives, essentially?  Or even worse, false negatives?  That's a huge problem.  How widespread is this?"
  },
  {
    "speaker": "Joe",
    "text": "It's incredibly widespread.  There was this study, a researcher named Carl Laflamme, he was looking at a protein linked to motor neuron disease. He found that out of sixteen commercially available antibodies supposedly targeting this specific protein, only *three* actually worked properly.  And the ones that *didn't* work?  They’d been used in, like, fifteen papers—cited over three thousand times!"
  },
  {
    "speaker": "Sarah",
    "text": "Whoa. Three thousand citations based on faulty data? That's… staggering.  What causes these antibodies to fail?  Is it just shoddy manufacturing?"
  },
  {
    "speaker": "Joe",
    "text": "It's not that simple.  It's a combination of factors. Sometimes the antibody doesn't bind strongly enough to its target protein – it lacks affinity. Other times, it binds to other proteins too – it lacks selectivity.  And, you know,  the process of producing antibodies is complex.  There's a lot of variability involved.  It's not always easy to get a consistently reliable product. Plus, a lot of the testing isn't always rigorous enough."
  },
  {
    "speaker": "Sarah",
    "text": "So, what's being done to fix this?  Is it just a matter of better manufacturing processes?"
  },
  {
    "speaker": "Joe",
    "text": "It's more than that.  There are several initiatives springing up.  One, called iCharOS – that's Icarus – aims to rigorously test *every* commercially available antibody targeting human proteins.  There's also a push for better standards, better testing protocols, and more transparency from antibody manufacturers. It's a multi-pronged approach."
  },
  {
    "speaker": "Sarah",
    "text": "That sounds promising.  It's a huge undertaking, though, right?  Testing every single antibody..."
  },
  {
    "speaker": "Joe",
    "text": "Oh yeah, it's a massive project.  But, um, it's crucial.  The consequences of unreliable antibodies are far-reaching.  It wastes time, money, and resources, and, more importantly, it could be slowing down scientific progress, potentially hindering drug development.  It's really a crisis of reproducibility in a lot of biomedical research."
  },
  {
    "speaker": "Sarah",
    "text": "It's a great example of how seemingly small, technical details can have enormous consequences.  Thanks for shedding light on this, Joe.  It's a problem I certainly wasn't aware of the full extent of."
  },
  {
    "speaker": "Joe",
    "text": "My pleasure, Sarah. It's a vital issue for the scientific community to address.  And that’s all the time we have for today’s episode of Science Odyssey. Join us next time for another fascinating journey into the world of scientific discovery!"
  }
]
[INFO] Processing 11 lines of text
[INFO] No speaker pattern match found at line 1: "**(Sound of a gentle transition, then silence)**..."
[INFO] Added conversation part: Joe with ** So, Sarah, that was a fascinating look at the a...
[INFO] Added conversation part: Sarah with **  It is mind-boggling, Joe. And the fact that tw...
[INFO] Added conversation part: Joe with ** Sure.  Rigorous validation, in the case of anti...
[INFO] Added conversation part: Sarah with **  So, it's a kind of control experiment, right? ...
[INFO] Added conversation part: Joe with ** Exactly.  It's a crucial negative control.  Wit...
[INFO] Added conversation part: Sarah with **  That's what I was getting at with the OMAPs in...
[INFO] Added conversation part: Joe with **  It's a monumental task, Sarah.  Feasible?  May...
[INFO] Added conversation part: Sarah with **  So, it's a bit like crowdsourcing validation, ...
[INFO] Added conversation part: Joe with ** That’s the million-dollar question, Sarah.  The...
[INFO] No speaker pattern match found at line 11: "**(Sound of a gentle transition, then silence)**..."
[INFO] Successfully extracted 9 conversation parts
[INFO] Cleaned Text (Chunk 2): [
  {
    "speaker": "Joe",
    "text": "** So, Sarah, that was a fascinating look at the antibody validation crisis, wasn't it?  The sheer number of antibodies on the market… it's staggering, really.  Seven point seven million…  I mean, just think about that for a second."
  },
  {
    "speaker": "Sarah",
    "text": "**  It is mind-boggling, Joe. And the fact that two-thirds of those tested by YCharOS didn't perform as advertised… that's a huge problem. It really highlights the need for rigorous validation, doesn't it?  But I'm curious, what exactly *is* rigorous validation in this context?  Can you break it down for our listeners?"
  },
  {
    "speaker": "Joe",
    "text": "** Sure.  Rigorous validation, in the case of antibodies, means carefully characterizing their specificity and selectivity. Specificity means the antibody only binds to its intended target protein, and nothing else. Selectivity means it binds strongly to that target, even when other similar proteins are present.  YCharOS uses a clever approach comparing the antibody's performance in a cell line expressing the target protein with a \"knock-out\" cell line lacking that protein.  If the antibody only binds to the cell line with the target protein, it's a good indication of specificity."
  },
  {
    "speaker": "Sarah",
    "text": "**  So, it's a kind of control experiment, right?  Like, a way to rule out false positives?"
  },
  {
    "speaker": "Joe",
    "text": "** Exactly.  It's a crucial negative control.  Without it, you could easily get false positives, where the antibody seems to be working, but it's actually binding to something else.  That's a major source of error in research.  Um… another aspect of validation is testing the antibody across different experimental conditions, though that's something even YCharOS can't fully address on its own."
  },
  {
    "speaker": "Sarah",
    "text": "**  That's what I was getting at with the OMAPs initiative, actually.  They're tackling the issue of context-dependent performance, aren't they?  It seems like a huge undertaking to validate antibodies across all possible applications and tissues.  Is that even feasible?"
  },
  {
    "speaker": "Joe",
    "text": "**  It's a monumental task, Sarah.  Feasible?  Maybe not completely, not in the foreseeable future.  But the collaborative approach of OMAPs, getting researchers from different labs and industries involved, is a really smart way to expand the scope of validation. It's like... you know, a distributed validation effort, leveraging the collective expertise and resources of the scientific community.  It's a necessary approach given the sheer scale of the problem.  Think about it – each lab might test a subset of conditions, adding to the overall picture."
  },
  {
    "speaker": "Sarah",
    "text": "**  So, it's a bit like crowdsourcing validation, but on a far more sophisticated and rigorous scale.  It makes sense, given the limitations of any single lab or company.  But it still leaves a lot of questions unanswered, doesn’t it?  How do we ensure the quality of all these antibodies in the long run? Is there a way to prevent this from happening again in the future?"
  },
  {
    "speaker": "Joe",
    "text": "** That’s the million-dollar question, Sarah.  There’s no single solution, unfortunately.  Improved manufacturing standards, more transparent data sharing, and stricter regulations are all part of the solution.  And initiatives like YCharOS and OMAPs are crucial steps towards building a more reliable system.  It's going to take a concerted effort from everyone involved – researchers, manufacturers, funding agencies – to truly address this challenge."
  }
]
[INFO] Processing 10 lines of text
[INFO] Added conversation part: Sarah with So, Joe, we've talked about the massive problem of...
[INFO] Added conversation part: Joe with Right, it's a multifaceted issue.  Um… let's see. ...
[INFO] Added conversation part: Sarah with So, it's like a universal identifier, making it ea...
[INFO] Added conversation part: Joe with Exactly.  That's where initiatives like YCharOS an...
[INFO] Added conversation part: Sarah with So, you have RRIDs for identification, and YCharOS...
[INFO] Added conversation part: Joe with Yeah, the scale is a huge challenge. There are mil...
[INFO] Added conversation part: Sarah with It sounds like a systemic problem that requires a ...
[INFO] Added conversation part: Joe with Precisely.  The Only Good Antibodies (OGA) communi...
[INFO] Added conversation part: Sarah with (laughs)  I appreciate you resisting the urge for ...
[INFO] Added conversation part: Joe with Exactly.  A very long marathon....
[INFO] Successfully extracted 10 conversation parts
[INFO] Cleaned Text (Chunk 3): [
  {
    "speaker": "Sarah",
    "text": "So, Joe, we've talked about the massive problem of unreliable antibodies in research.  You mentioned several initiatives – YCharOS, OMAPs, RRIDs –  but it still sounds incredibly complex.  Can you break down how these different approaches work together, or even if they *do* work together?"
  },
  {
    "speaker": "Joe",
    "text": "Right, it's a multifaceted issue.  Um… let's see.  RRIDs, the Research Resource Identifiers, are basically unique ID numbers for antibodies and other research materials.  Think of them like product barcodes, but specifically designed for scientific resources.  They help track down the exact antibody used in a study, even if the manufacturer changes or discontinues the product.  It's a crucial first step in reproducibility, because if you can't even find the same antibody, you can't replicate the experiment, right?"
  },
  {
    "speaker": "Sarah",
    "text": "So, it's like a universal identifier, making it easier to find specific antibodies mentioned in papers.  But that doesn't solve the problem of the antibody itself being unreliable, does it?"
  },
  {
    "speaker": "Joe",
    "text": "Exactly.  That's where initiatives like YCharOS and OMAPs come in.  They focus on characterizing antibodies – rigorously testing them to see how well they perform.  YCharOS, for example, provides detailed data on the specificity and sensitivity of antibodies.  This data, ideally, should be readily available,  and platforms like CiteAb are integrating this information so researchers can make informed choices.  OMAPs… well, that’s a bit more complex, involving…  it's essentially a community effort to standardize antibody validation methods."
  },
  {
    "speaker": "Sarah",
    "text": "So, you have RRIDs for identification, and YCharOS and OMAPs for quality control and validation. But it sounds like even with all these initiatives, there's still a long way to go.  What are the biggest hurdles, you know, besides the sheer volume of antibodies out there?"
  },
  {
    "speaker": "Joe",
    "text": "Yeah, the scale is a huge challenge. There are millions of antibodies, and validating them all is a monumental task.  Another significant hurdle is the lack of standardization.  Different labs use different methods for validation, making it difficult to compare results.  And then there's the issue of incentives.  Manufacturers might not prioritize rigorous validation if it's not financially beneficial for them.  So, you need a combination of technological solutions, like the databases and identifiers, along with regulatory changes and a shift in the research culture itself."
  },
  {
    "speaker": "Sarah",
    "text": "It sounds like a systemic problem that requires a collaborative effort from everyone involved.  It's not just about the tech; it's about changing the way research is done and funded, right?"
  },
  {
    "speaker": "Joe",
    "text": "Precisely.  The Only Good Antibodies (OGA) community is a great example of that collaborative effort.  They're bringing together researchers, manufacturers, funding agencies – all the stakeholders – to discuss and implement solutions.  It's a long-term project, but it's a necessary one.  You know, it's a bit like…  (pauses)  No, let's not use an analogy.  It's a complex issue requiring a multifaceted approach."
  },
  {
    "speaker": "Sarah",
    "text": "(laughs)  I appreciate you resisting the urge for analogies!  It makes it much clearer.  So, in short, we need better identifiers, better validation methods, a more collaborative approach, and maybe some regulatory changes to really tackle this problem.  It's a marathon, not a sprint."
  },
  {
    "speaker": "Joe",
    "text": "Exactly.  A very long marathon."
  }
]
[INFO] Processing 9 lines of text
[INFO] Added conversation part: Joe with So, Sarah, that was… a marathon, wasn't it?  A lot...
[INFO] Added conversation part: Sarah with Right. And that's a huge shift, isn't it?  It soun...
[INFO] Added conversation part: Joe with Okay, so the traditional methods, using hybridomas...
[INFO] Added conversation part: Sarah with So, it's like... a recipe, but instead of baking a...
[INFO] Added conversation part: Joe with It's not a bad analogy, but it's more precise than...
[INFO] Added conversation part: Sarah with Okay, I think I get that.  But even with this more...
[INFO] Added conversation part: Joe with Partly, yes, but also habit, inertia, and perhaps ...
[INFO] Added conversation part: Sarah with So it's a combination of factors – the cost of cha...
[INFO] Added conversation part: Joe with Exactly. It's not just about the technology; it's ...
[INFO] Successfully extracted 9 conversation parts
[INFO] Cleaned Text (Chunk 4): [
  {
    "speaker": "Joe",
    "text": "So, Sarah, that was… a marathon, wasn't it?  A lot of information on antibody reliability and reproducibility.  The core issue, as I see it, boils down to the shift from antibodies produced using traditional methods – you know, from immune cells or hybridomas – to recombinant antibodies."
  },
  {
    "speaker": "Sarah",
    "text": "Right. And that's a huge shift, isn't it?  It sounds like a pretty fundamental change in how these things are made. Can you break down *why* recombinant antibodies are so much better?  I mean, I get the \"infinite production\" part, but what's the technical reason behind the improved reproducibility?"
  },
  {
    "speaker": "Joe",
    "text": "Okay, so the traditional methods, using hybridomas, are inherently variable.  The process of creating and growing these cell lines is complex, and slight variations in culture conditions, even minor genetic drift within the hybridoma population, can lead to differences in the antibody produced from batch to batch.  Recombinant antibodies, on the other hand, are produced using genetically engineered cells.  Think of it as a precise, repeatable manufacturing process.  You have a defined DNA sequence encoding the specific antibody you want, and you use that to create cells that consistently produce that exact antibody.  There's less room for error, for variation.  It's all much more controlled."
  },
  {
    "speaker": "Sarah",
    "text": "So, it's like... a recipe, but instead of baking a cake, you're making antibodies?  Is that a fair analogy?"
  },
  {
    "speaker": "Joe",
    "text": "It's not a bad analogy, but it's more precise than that.  A recipe can still have variations depending on the baker, right?  With recombinant antibody production,  the \"recipe\" – the DNA sequence – is fixed, and the \"baking process\" – the cell culture – is standardized to minimize variation.  It’s more like a highly automated factory producing identical products."
  },
  {
    "speaker": "Sarah",
    "text": "Okay, I think I get that.  But even with this more controlled process, you mentioned there's still resistance from some researchers.  Why is that?  Is it just stubbornness?"
  },
  {
    "speaker": "Joe",
    "text": "Partly, yes, but also habit, inertia, and perhaps a lack of awareness of the benefits.  Some researchers might have been using a particular antibody for years, and they’re hesitant to switch, even if there's evidence suggesting it's not as reliable as a recombinant alternative.  There's also the time and effort involved in validating a new antibody.  It’s not a trivial process."
  },
  {
    "speaker": "Sarah",
    "text": "So it's a combination of factors – the cost of changing, the time investment in validation, and maybe even a bit of resistance to change? That makes sense.  It sounds like a long road ahead to get everyone on board with the recombinant method."
  },
  {
    "speaker": "Joe",
    "text": "Exactly. It's not just about the technology; it's about changing the culture of research, too.  The good news is that initiatives like the ones discussed, promoting best practices and rewarding researchers for using validated antibodies, are starting to make a difference.  It's a slow process, but I'm optimistic things are moving in the right direction.  The younger generation seems particularly keen on improving reproducibility."
  }
]
[INFO] 

 ==================Last Chunk===================

[INFO] Processing 14 lines of text
[INFO] Added conversation part: Sarah with So, Joe, you were just saying about validating ant...
[INFO] Added conversation part: Joe with Sure.  There are several key methods. Um, one is i...
[INFO] Added conversation part: Sarah with Okay, so it's a visual test, almost?  Like, you ca...
[INFO] Added conversation part: Joe with Exactly.  Another method is Western blotting. This...
[INFO] Added conversation part: Sarah with I see. So, Western blotting gives you a more preci...
[INFO] Added conversation part: Joe with Precisely. And then there's immunoprecipitation.  ...
[INFO] Added conversation part: Sarah with So, you're basically using the antibody as a tool ...
[INFO] Added conversation part: Joe with Absolutely.  Even with these methods, there are li...
[INFO] Added conversation part: Sarah with It’s a lot to keep track of.  It sounds incredibly...
[INFO] Added conversation part: Joe with It really is. And it's a big part of why we're see...
[INFO] Added conversation part: Sarah with That’s reassuring to hear.  Thanks for explaining ...
[INFO] Added conversation part: Joe with My pleasure, Sarah.  It's a complex area, but cruc...
[INFO] Added conversation part: Sarah with Definitely....
[INFO] Added conversation part: Joe with Thank you for joining us on this episode of Scienc...
[INFO] Successfully extracted 14 conversation parts
[INFO] Cleaned Text (Chunk 5): [
  {
    "speaker": "Sarah",
    "text": "So, Joe, you were just saying about validating antibodies.  That sounds… complicated. Can you break that down a bit more for our listeners?  What are the main ways researchers do this?"
  },
  {
    "speaker": "Joe",
    "text": "Sure.  There are several key methods. Um, one is immunohistochemistry.  Basically, you're using an antibody to label cells that express a specific protein.  If the antibody is good, it’ll only bind to the cells that actually have that protein.  You know, it's like...  well, forget the analogy. It's a direct test of whether the antibody binds to the right thing in its natural environment, within the cells."
  },
  {
    "speaker": "Sarah",
    "text": "Okay, so it's a visual test, almost?  Like, you can see which cells are labeled?"
  },
  {
    "speaker": "Joe",
    "text": "Exactly.  Another method is Western blotting. This one's a bit different.  Here, you're using the antibody to detect a specific protein in a sample that's been separated by size using gel electrophoresis.  If the antibody is specific, it will only bind to the protein band with the expected molecular weight.  It's like... you're looking for a specific person in a lineup, based on their height and weight."
  },
  {
    "speaker": "Sarah",
    "text": "I see. So, Western blotting gives you a more precise measurement of the protein size as well.  That's helpful for confirming identity, right?  Because sometimes proteins can be similar in structure."
  },
  {
    "speaker": "Joe",
    "text": "Precisely. And then there's immunoprecipitation.  This is where you use the antibody to physically pull out the protein of interest from a complex mixture of proteins.  Then, you can analyze what you've pulled out using something like mass spectrometry to confirm its identity.  It's a much more rigorous way to confirm that you're actually interacting with the protein you think you are."
  },
  {
    "speaker": "Sarah",
    "text": "So, you're basically using the antibody as a tool to isolate the protein and then independently verify its identity.  That makes sense.  It sounds like a pretty thorough process, but still… there's room for error, I guess?"
  },
  {
    "speaker": "Joe",
    "text": "Absolutely.  Even with these methods, there are limitations.  And, you know, sometimes researchers might cut corners or misinterpret results.  That's why having standardized protocols and rigorous quality control are so important."
  },
  {
    "speaker": "Sarah",
    "text": "It’s a lot to keep track of.  It sounds incredibly detailed and meticulous.  And yet, it is crucial to the whole process."
  },
  {
    "speaker": "Joe",
    "text": "It really is. And it's a big part of why we're seeing such an emphasis on reproducibility in science right now.  It's not just about the technology; it's about changing the culture of research, too. The good news is that initiatives promoting best practices and rewarding researchers for using validated antibodies are starting to make a difference.  It's a slow process, but I'm optimistic things are moving in the right direction. The younger generation seems particularly keen on improving reproducibility."
  },
  {
    "speaker": "Sarah",
    "text": "That’s reassuring to hear.  Thanks for explaining all of that, Joe. It’s clear there's a lot more to it than just throwing an antibody at a sample."
  },
  {
    "speaker": "Joe",
    "text": "My pleasure, Sarah.  It's a complex area, but crucial for the reliability of scientific findings."
  },
  {
    "speaker": "Sarah",
    "text": "Definitely."
  },
  {
    "speaker": "Joe",
    "text": "Thank you for joining us on this episode of Science Odyssey, where we explored the groundbreaking research shaping our understanding of the world. If you enjoyed this journey, don't forget to subscribe, leave a review, and share the podcast with fellow science enthusiasts. Until next time, keep exploring the wonders of science—your next discovery awaits!"
  }
]
[INFO] 
======= Starting Pricing Calculation ======
 -Input text length: 16704
 -Number of Vertex AI responses: 5

[INFO] 
        Input text length: 16704
        Input token count: 3419
        System prompt length: 2718
        System token count: 525
        Total input tokens: 3944
      
[INFO] Response 1 details:
- Length: 3386 characters
- Output tokens: 765
[INFO] Response 2 details:
- Length: 3456 characters
- Output tokens: 766
[INFO] Response 3 details:
- Length: 3397 characters
- Output tokens: 749
[INFO] Response 4 details:
- Length: 3063 characters
- Output tokens: 673
[INFO] Response 5 details:
- Length: 3476 characters
- Output tokens: 776
[INFO] Total TTS characters calculated: 16535
[INFO] 
---***** Final Pricing Calculation Summary **** ---
Total Input Tokens: 3944
Total Output Tokens: 3729
Total Tokens: 7673
Total TTS Characters: 16535
Vertex AI Input Cost: $0.000002
Vertex AI Output Cost: $0.000002
TTS Cost: $0.264560
Total Cost: $0.264564
[INFO] Generating audio files...
[INFO] Usage check for user: inactive
[INFO] GET /api/user/usage/check 304 in 113ms
[INFO] Audio content written to file "audio-files/0.mp3"
[INFO] Audio content written to file "audio-files/1.mp3"
[INFO] Usage check for user: inactive
[INFO] GET /api/user/usage/check 304 in 113ms
[INFO] Audio content written to file "audio-files/2.mp3"
[INFO] Audio content written to file "audio-files/3.mp3"
[ERROR] Webhook signature verification failed: No signatures found matching the expected signature for payload. Are you passing the raw request body you received from Stripe? 
 If a webhook request is being forwarded by a third-party tool, ensure that the exact request body, including JSON formatting and new line style, is preserved.

Learn more about webhook signing and explore webhook integration examples for various frameworks at https://docs.stripe.com/webhooks/signature

[INFO] POST /api/webhooks/stripe 400 in 1ms
[INFO] Usage check for user: inactive
[INFO] GET /api/user/usage/check 304 in 113ms
[INFO] Audio content written to file "audio-files/4.mp3"
[INFO] Audio content written to file "audio-files/5.mp3"
[ERROR] Webhook signature verification failed: No signatures found matching the expected signature for payload. Are you passing the raw request body you received from Stripe? 
 If a webhook request is being forwarded by a third-party tool, ensure that the exact request body, including JSON formatting and new line style, is preserved.

Learn more about webhook signing and explore webhook integration examples for various frameworks at https://docs.stripe.com/webhooks/signature

[INFO] POST /api/webhooks/stripe 400 in 1ms
[INFO] Usage check for user: inactive
[INFO] GET /api/user/usage/check 304 in 112ms
[INFO] Audio content written to file "audio-files/6.mp3"
[INFO] Audio content written to file "audio-files/7.mp3"
[INFO] Usage check for user: inactive
[INFO] GET /api/user/usage/check 304 in 112ms
[INFO] Audio content written to file "audio-files/8.mp3"
[INFO] Audio content written to file "audio-files/9.mp3"
[INFO] Usage check for user: inactive
[INFO] GET /api/user/usage/check 304 in 118ms
[INFO] Audio content written to file "audio-files/10.mp3"
[INFO] Audio content written to file "audio-files/11.mp3"
[INFO] Usage check for user: inactive
[INFO] GET /api/user/usage/check 304 in 112ms
[INFO] Audio content written to file "audio-files/12.mp3"
[INFO] Audio content written to file "audio-files/13.mp3"
[INFO] Usage check for user: inactive
[INFO] GET /api/user/usage/check 304 in 113ms
[INFO] Audio content written to file "audio-files/14.mp3"
[INFO] Audio content written to file "audio-files/15.mp3"
[INFO] Audio content written to file "audio-files/16.mp3"
[INFO] Audio content written to file "audio-files/17.mp3"
[INFO] Audio content written to file "audio-files/18.mp3"
[INFO] Audio content written to file "audio-files/19.mp3"
[INFO] Audio content written to file "audio-files/20.mp3"
[INFO] Audio content written to file "audio-files/21.mp3"
[INFO] Audio content written to file "audio-files/22.mp3"
[INFO] Audio content written to file "audio-files/23.mp3"
[INFO] Audio content written to file "audio-files/24.mp3"
[INFO] Audio content written to file "audio-files/25.mp3"
[INFO] Usage check for user: inactive
[INFO] GET /api/user/usage/check 304 in 113ms
[INFO] Audio content written to file "audio-files/26.mp3"
[INFO] Usage check for user: inactive
[INFO] GET /api/user/usage/check 304 in 112ms
[INFO] Audio content written to file "audio-files/27.mp3"
[INFO] Audio content written to file "audio-files/28.mp3"
[INFO] Audio content written to file "audio-files/29.mp3"
[INFO] Audio content written to file "audio-files/30.mp3"
[INFO] Usage check for user: inactive
[INFO] GET /api/user/usage/check 304 in 114ms
[INFO] Audio content written to file "audio-files/31.mp3"
[INFO] Audio content written to file "audio-files/32.mp3"
[INFO] Usage check for user: inactive
[INFO] GET /api/user/usage/check 304 in 111ms
[INFO] Audio content written to file "audio-files/33.mp3"
[INFO] Usage check for user: inactive
[INFO] GET /api/user/usage/check 304 in 114ms
[INFO] Audio content written to file "audio-files/34.mp3"
[INFO] Audio content written to file "audio-files/35.mp3"
[INFO] Usage check for user: inactive
[INFO] GET /api/user/usage/check 304 in 112ms
[INFO] Audio content written to file "audio-files/36.mp3"
[INFO] Audio content written to file "audio-files/37.mp3"
[INFO] Usage check for user: inactive
[INFO] GET /api/user/usage/check 304 in 116ms
[INFO] Audio content written to file "audio-files/38.mp3"
[INFO] Audio content written to file "audio-files/39.mp3"
[INFO] Usage check for user: inactive
[INFO] GET /api/user/usage/check 304 in 115ms
[INFO] Audio content written to file "audio-files/40.mp3"
[INFO] Audio content written to file "audio-files/41.mp3"
[INFO] Usage check for user: inactive
[INFO] GET /api/user/usage/check 304 in 112ms
[INFO] Audio content written to file "audio-files/42.mp3"
[INFO] Audio content written to file "audio-files/43.mp3"
[INFO] Usage check for user: inactive
[INFO] GET /api/user/usage/check 304 in 112ms
[INFO] Audio content written to file "audio-files/44.mp3"
[INFO] Audio content written to file "audio-files/45.mp3"
[INFO] Usage check for user: inactive
[INFO] GET /api/user/usage/check 304 in 113ms
[INFO] Audio content written to file "audio-files/46.mp3"
[INFO] Audio content written to file "audio-files/47.mp3"
[INFO] Usage check for user: inactive
[INFO] GET /api/user/usage/check 304 in 112ms
[INFO] Audio content written to file "audio-files/48.mp3"
[INFO] Audio content written to file "audio-files/49.mp3"
[INFO] Usage check for user: inactive
[INFO] GET /api/user/usage/check 304 in 111ms
[INFO] Audio content written to file "audio-files/50.mp3"
[INFO] Audio content written to file "audio-files/51.mp3"
[INFO] Audio content written to file "audio-files/52.mp3"
[INFO] Audio content written to file "audio-files/53.mp3"
[INFO] Usage check for user: inactive
[INFO] GET /api/user/usage/check 304 in 112ms
[INFO] Audio content written to file "audio-files/54.mp3"
[INFO] Copied intro file podcast.mp3 to audio folder
[INFO] Merging the following files in order:
[INFO] 0.mp3
[INFO] 1.mp3
[INFO] 3.mp3
[INFO] 5.mp3
[INFO] 6.mp3
[INFO] 7.mp3
[INFO] 8.mp3
[INFO] 9.mp3
[INFO] 2.mp3
[INFO] 10.mp3
[INFO] 4.mp3
[INFO] 12.mp3
[INFO] 11.mp3
[INFO] 13.mp3
[INFO] 14.mp3
[INFO] 15.mp3
[INFO] 16.mp3
[INFO] 17.mp3
[INFO] 18.mp3
[INFO] 19.mp3
[INFO] 20.mp3
[INFO] 21.mp3
[INFO] 22.mp3
[INFO] 23.mp3
[INFO] 24.mp3
[INFO] 25.mp3
[INFO] 26.mp3
[INFO] 27.mp3
[INFO] 29.mp3
[INFO] 28.mp3
[INFO] 30.mp3
[INFO] 31.mp3
[INFO] 32.mp3
[INFO] 33.mp3
[INFO] 34.mp3
[INFO] 35.mp3
[INFO] 36.mp3
[INFO] 37.mp3
[INFO] 38.mp3
[INFO] 39.mp3
[INFO] 40.mp3
[INFO] 42.mp3
[INFO] 41.mp3
[INFO] 43.mp3
[INFO] 44.mp3
[INFO] 45.mp3
[INFO] 46.mp3
[INFO] 47.mp3
[INFO] 48.mp3
[INFO] 49.mp3
[INFO] 51.mp3
[INFO] 50.mp3
[INFO] 52.mp3
[INFO] 53.mp3
[INFO] 54.mp3
[INFO] Successfully merged audio saved as audio-files/final_output.mp3
[INFO] Cleaned up audio-files directory after successful generation
[INFO] Audio generation completed: Duration: 811s Actual tokens used: 7673 Actual cost: 0.2645638365
[INFO] 

---------- Updated Usage ----------
 Updated usage for user 26:
 Articles: 2/3
 Podify Tokens: 167/10000
[INFO] Successfully saved audio file (audio/mpeg) to Object Storage: 1735925804169-article.mp3
[INFO] Successfully created podcast entry with ID: 36
[INFO] POST /api/podcast 200 in 196191ms
[INFO] Usage check for user: inactive
[INFO] GET /api/user/usage/check 200 in 4858ms
[INFO] GET / 200 in 65ms
[INFO] 
========Streaming audio file: 1735923996260-article.mp3
[ERROR] File not found in Object Storage: 1735923996260-article.mp3
[INFO] GET /api/audio/stream/1735923996260-article.mp3 404 in 166ms
[INFO] GET /api/podcasts 200 in 221ms
[INFO] 
========Streaming audio file: 1735923996260-article.mp3
[ERROR] File not found in Object Storage: 1735923996260-article.mp3
[INFO] GET /api/audio/stream/1735923996260-article.mp3 404 in 60ms
[INFO] 
========Streaming audio file: 1735925804169-article.mp3
[ERROR] File not found in Object Storage: 1735925804169-article.mp3
[INFO] HEAD /api/audio/stream/1735925804169-article.mp3 404 in 60ms
